ResMed Inc (RMD)

Currency in USD
225.01
-3.11(-1.36%)
Real-time Data·
Earnings results expected in 10 days
RMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
224.30229.30
52 wk Range
209.31293.81
Key Statistics
Prev. Close
228.12
Open
227.98
Day's Range
224.3-229.3
52 wk Range
209.31-293.81
Volume
468.41K
Average Volume (3m)
1.1M
1-Year Change
6.9325%
Book Value / Share
43.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
292.33
Upside
+29.92%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years

ResMed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Inc SWOT Analysis


Sleep Tech Dominance
ResMed's strong market position in sleep and respiratory care, driven by innovative products like AirSense 11, faces potential disruption from emerging GLP-1 drugs
Financial Resilience
Explore ResMed's impressive financial performance, with double-digit revenue growth and improved operating margins, despite challenges in gross margins
Market Expansion
Delve into ResMed's strategic moves beyond sleep apnea, targeting insomnia and COPD markets to diversify revenue streams and offset potential market share losses
Analyst Perspectives
Price targets range from $180 to $280, reflecting varied views on ResMed's ability to navigate challenges from GLP-1 drugs and increased competition
Read full SWOT analysis

ResMed Inc Earnings Call Summary for Q2/2026

  • ResMed reported Q2 2026 EPS of $2.81, beating forecasts by 2.93%, with revenue meeting expectations at $1.4 billion despite a 0.51% stock dip in aftermarket trading.
  • The company achieved 11% revenue growth and 19% increase in operating profits, with operating margin improving to 36.3% and net income rising 15% year-over-year.
  • Management projects FY2026 gross margin of 62-63% with an effective tax rate of 21-23%, while increasing share repurchases to over $600 million.
  • CEO Mick Farrell emphasized the company's long-term vision, stating 'We're in mile one of the marathon' and noting the growing importance of sleep health in healthcare.
  • Potential challenges include restructuring charges, supply chain disruptions, intensifying market competition, and macroeconomic pressures including currency fluctuations.
Last Updated: 01/30/2026, 06:46 AM
Read Full Transcript

Compare RMD to Peers and Sector

Metrics to compare
RMD
Peers
Sector
Relationship
P/E Ratio
22.0x18.4x−0.5x
PEG Ratio
1.150.810.00
Price/Book
5.2x2.0x2.6x
Price / LTM Sales
6.1x1.7x3.2x
Upside (Analyst Target)
27.0%26.9%44.2%
Fair Value Upside
Unlock22.8%5.5%Unlock

Analyst Ratings

10 Buy
7 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 292.33
(+29.92% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy---New CoverageApr 15, 2026
Baird
Hold254.00+12.88%272.00MaintainApr 15, 2026
Mizuho
Buy255.00+13.32%300.00MaintainApr 13, 2026
Stifel
Hold265.00+17.77%265.00MaintainMar 16, 2026
Baird
Hold272.00+20.88%281.00MaintainMar 11, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.11%
Dividend Yield
1.07%
Industry Median 1.46%
Annualized payout
2.40
Paid quarterly
5-Years Growth
+7.70%
Growth Streak

Earnings

Latest Release
Jan 29, 2026
EPS / Forecast
2.81 / 2.73
Revenue / Forecast
1.4B / 1.4B
EPS Revisions
Last 90 days

RMD Income Statement

People Also Watch

402.52
INTU
+2.36%
244.68
ADSK
+1.10%
111.18
DECK
-1.17%
64.32
FISV
+0.55%
248.34
ADBE
+1.59%

FAQ

What Is the ResMed (RMD) Stock Price Today?

The ResMed stock price today is 225.01 USD.

What Stock Exchange Does ResMed Trade On?

ResMed is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for ResMed?

The stock symbol for ResMed is "RMD."

Does ResMed Pay Dividends? What’s The Current Dividend Yield?

The ResMed dividend yield is 1.07%.

What Is the ResMed Market Cap?

As of today, ResMed market cap is 32.68B USD.

What Is ResMed's Earnings Per Share (TTM)?

The ResMed EPS (TTM) is 10.11.

When Is the Next ResMed Earnings Date?

ResMed will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is RMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ResMed Stock Split?

ResMed has split 4 times.

How Many Employees Does ResMed Have?

ResMed has 10600 employees.

What is the current trading status of ResMed (RMD)?

As of Apr 20, 2026, ResMed (RMD) is trading at a price of 225.01 USD, with a previous close of 228.12 USD. The stock has fluctuated within a day range of 224.30 USD to 229.30 USD, while its 52-week range spans from 209.31 USD to 293.81 USD.

What Is ResMed (RMD) Price Target According to Analysts?

The average 12-month price target for ResMed is 292.33 USD, with a high estimate of 345 USD and a low estimate of 230 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +29.92% Upside potential.

What Is the RMD Premarket Price?

RMD's last pre-market stock price is 226.61 USD. The pre-market share volume is 100.00, and the stock has decreased by -1.51, or -0.66%.

What Is the RMD After Hours Price?

RMD's last after hours stock price is 226.79 USD, the stock has decreased by -1.33, or -0.58%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.